Dry Eye Disease (DED) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033


 Dry eye disease (DED), also referred to as keratoconjunctivitis sicca, is a prevalent and persistent condition affecting the ocular surface. It is characterized by an inability to produce an adequate quantity or quality of tears to moisturize the eyes. Several common risk factors contribute to this syndrome, including aging, being female, exposure to low-humidity environments, using certain systemic medications, and autoimmune disorders. DED is categorized into two main types: "dry eye with reduced tear production," referred to as aqueous deficient, and "dry eye with increased tear film evaporation," known as the hyper-evaporative type. Among those affected, about 10% suffer from aqueous deficient DED, while more than 80% experience the hyper-evaporative type, often related to meibomian gland dysfunction (MGD) or a combination of both. The consequences of DED can be substantial, significantly impacting one's vision and overall quality of life. The associated symptoms often interfere with everyday tasks such as writing, reading, or working on video display monitors. Consequently, the primary objectives of DED treatment are to alleviate ocular discomfort, enhance the patient's quality of life, and restore the ocular surface and tear film to their natural states, preventing any further harm to the eye tissue and cornea. Various pharmacological therapies are available as part of the treatment arsenal.

·       The prevalence of DED in the general population stands at 5.28%. The condition is more prevalent among females, affecting 7.78%, compared to 2.96% among males. Furthermore, DED becomes more common with age, with a rate of 0.20% among those aged 2-17 years, increasing significantly to 11.66% for individuals aged 50 years or older.

·       The annual prevalence rates show an upward trend, rising from 0.8% to 3.0% overall, from 1.4% to 4.5% in females, and from 0.3% to 1.6% in males.

 

Thelansis’s “Dry Eye Disease (DED) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Dry Eye Disease (DED) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

 

KOLs insights of Dry Eye Disease (DED) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Dry Eye Disease (DED) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Dry Eye Disease (DED) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Tags: Dry Eye Disease (DED), Dry Eye Disease (DED) market outlook, Dry Eye Disease (DED) competitive landscape, Dry Eye Disease (DED) market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)

Comments

Post a Comment

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Image
  Acne vulgaris, a prevalent pilosebaceous unit inflammatory skin disorder, follows a persistent course. Typically presenting as papules, pustules, or nodules, it primarily occurs on the face but can also impact the upper arms, trunk, and back. The development of acne results from the sebaceous glands' heightened sensitivity to normal androgen levels, aggravated by Cutibacterium acnes (formerly known as Propionibacterium acnes), a bacterial species that triggers inflammation. The pathogenesis of acne vulgaris involves a complex interplay of factors such as the activation of sebaceous glands by androgens, imbalances in the pilosebaceous follicle microbiome, and cellular immune responses. Genetic predisposition and dietary influences also contribute to the condition's onset and progression. The initial stage is the micro-comedo, a small plug primarily composed of corneocytes in the lower follicular infundibulum. Microcomedones evolve into various acne lesions, including closed co...
Read more

Herpes Simplex Virus (HSV) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
 Herpes simplex virus (HSV) causes an infection that affects the external genitalia, anal region, mucosal surfaces, and skin in other body parts. Herpes simplex virus is a ubiquitous, host-adapted pathogen that causes various disease states. There are two types of HSV with two distinct DNA viruses, type 1 (HSV-1) and type 2 (HSV-2). Both the types are closely related but differ epidemiologically. HSV-1 is traditionally associated with orofacial disease by affecting the mouth and lips with fever blisters and cold sores, whereas HSV-2 is associated traditionally with genital disease infecting genitals and rectum area with sores and is classified as STD (sexually transmitted disease). As HSV-1 is associated with genital infections more often than HSV-2, lesion location is not necessarily of viral type. HSV can spread through direct contact. Almost 80% of Herpes simplex infections are asymptomatic, while symptomatic infections can be characterized by significant morbidity and recurrenc...
Read more

HR+/HER2- Breast Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
Thelansis’s “HR+/HER2- Breast Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential HR+/HER2- Breast Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). KOLs insights of HR+/HER2- Breast Cancer across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs. HR+/HER2- Breast Cancer Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model,...
Read more